232 related articles for article (PubMed ID: 7812972)
1. Cell proliferation kinetics in human tumor xenografts measured with iododeoxyuridine labeling and flow cytometry: a study of heterogeneity and a comparison between different methods of calculation and other proliferation measurements.
Perez LA; Dombkowski D; Efird J; Preffer F; Suit HD
Cancer Res; 1995 Jan; 55(2):392-8. PubMed ID: 7812972
[TBL] [Abstract][Full Text] [Related]
2. Influence of sampling time on assessment of potential doubling time.
Høyer M; Bentzen SM; Salling LN; Overgaard J
Cytometry; 1994 Jun; 16(2):144-51. PubMed ID: 7924683
[TBL] [Abstract][Full Text] [Related]
3. Comparison of BrdUrd and [3H]TdR incorporation to estimate cell proliferation, cell loss, and potential doubling time in tumor xenografts.
Zätterström UK; Johansson M; Källén A; Baldetorp B; Oredsson S; Wennerberg J; Killander D
Cytometry; 1992; 13(8):872-9. PubMed ID: 1459003
[TBL] [Abstract][Full Text] [Related]
4. Measurement of potential doubling time for human tumor xenografts using the cytokinesis-block method.
Hlatky L; Olesiak M; Hahnfeldt P
Cancer Res; 1996 Apr; 56(7):1660-3. PubMed ID: 8603417
[TBL] [Abstract][Full Text] [Related]
5. [Cell kinetic analysis and treatment planning in epidermoid tumors of the head and neck].
Margarino G; Scala M; Schenone G; Mereu P; Corvo R; Sanguineti G; Giaretti W; Geido E; Orecchia R; Meszaros P
Acta Otorhinolaryngol Ital; 1992; 12(5):421-33. PubMed ID: 1303006
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen-induced increase in the potential doubling time of MCF-7 xenografts as determined by bromodeoxyuridine labeling and flow cytometry.
Sarkaria JN; Gibson DF; Jordan VC; Fowler JF; Lindstrom MJ; Mulcahy RT
Cancer Res; 1993 Sep; 53(18):4413-7. PubMed ID: 8364937
[TBL] [Abstract][Full Text] [Related]
7. Measurement of thymidine replacement in patients with high grade gliomas, head and neck tumors, and high grade sarcomas after continuous intravenous infusions of 5-iododeoxyuridine.
Cook JA; Glass J; Lebovics R; Bobo H; Pass H; DeLaney TF; Oldfield EH; Mitchell JB; Glatstein E; Goffman TE
Cancer Res; 1992 Feb; 52(3):719-25. PubMed ID: 1732059
[TBL] [Abstract][Full Text] [Related]
8. Cell proliferation in renal cell carcinoma. A clinical study with special reference to prognosis.
Larsson P
Scand J Urol Nephrol Suppl; 1994; 165():1-48. PubMed ID: 7871395
[TBL] [Abstract][Full Text] [Related]
9. DNA--cytometric studies on xenografts of squamous cell carcinomas of the head and neck.
Elprana D; Kuijpers W; Peperkamp AR; Wagener DJ
Anticancer Res; 1991; 11(5):1943-9. PubMed ID: 1768066
[TBL] [Abstract][Full Text] [Related]
10. Measurement of proliferation activities in human tumor models: a comparison of flow cytometric methods.
Keng PC; Siemann DW
Radiat Oncol Investig; 1998; 6(3):120-7. PubMed ID: 9652910
[TBL] [Abstract][Full Text] [Related]
11. Cell cycle time, growth fraction and cell loss in xenografted head and neck cancer.
Zätterström UK; Källén A; Wennerberg J
In Vivo; 1991; 5(2):137-42. PubMed ID: 1768782
[TBL] [Abstract][Full Text] [Related]
12. Tumor cell kinetics using two labels and flow cytometry.
Ritter MA; Fowler JF; Kim YJ; Gilchrist KW; Morrissey LW; Kinsella TJ
Cytometry; 1994 May; 16(1):49-58. PubMed ID: 8033734
[TBL] [Abstract][Full Text] [Related]
13. Establishment and characterization of five new human renal tumor xenografts.
Beniers AJ; Peelen WP; Schaafsma HE; Beck JL; Ramaekers FC; Debruyne FM; Schalken JA
Am J Pathol; 1992 Feb; 140(2):483-95. PubMed ID: 1739137
[TBL] [Abstract][Full Text] [Related]
14. The effect of high dose vitamin A on the morphology and proliferative activity of xenograft lung and head and neck cancer.
Mourad WA; Bruner JM; Vallieres E; McName C; Alabdulwahed S; Scott K; Oldring DJ
In Vivo; 1996; 10(3):329-33. PubMed ID: 8797035
[TBL] [Abstract][Full Text] [Related]
15. The decreased influence of overall treatment time on the response of human breast tumor xenografts following prolongation of the potential doubling time (Tpot).
Sarkaria JN; Fowler JF; Lindstrom MJ; Jordan VC; Mulcahy RT
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):833-40. PubMed ID: 7860396
[TBL] [Abstract][Full Text] [Related]
16. Human-in-mouse modeling of primary head and neck squamous cell carcinoma.
Law JH; Whigham AS; Wirth PS; Liu D; Pham MQ; Vadivelu S; Kirkbride KC; Brown BT; Burkey BB; Sinard RJ; Netterville JL; Yarbrough WG
Laryngoscope; 2009 Dec; 119(12):2315-23. PubMed ID: 19693929
[TBL] [Abstract][Full Text] [Related]
17. Measurement of the proliferative activity of three different sublines of the Dunning rat prostate tumor R3327.
Lohr F; Wenz F; Flentje M; Peschke P; Hahn EW
Strahlenther Onkol; 1993 Jul; 169(7):438-45. PubMed ID: 8342118
[TBL] [Abstract][Full Text] [Related]
18. DNA ploidy, proliferative capacity and intratumoral heterogeneity in primary and recurrent head and neck squamous cell carcinomas (HNSCC)--potential implications for clinical management and treatment decisions.
Hass HG; Schmidt A; Nehls O; Kaiser S
Oral Oncol; 2008 Jan; 44(1):78-85. PubMed ID: 17350326
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous cell kinetics in tumors analyzed with a simulation model for bromodeoxyuridine single and multiple labeling.
Baisch H; Otto U; Hatje U; Fack H
Cytometry; 1995 Sep; 21(1):52-61. PubMed ID: 8529471
[TBL] [Abstract][Full Text] [Related]
20. [Correlation analysis of radiation effects on potential doubling time (Tpot) for human nasopharyngeal carcinoma cells].
Zhu J; Cao S; Cao X
Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):427-30. PubMed ID: 10920874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
